Tech Company Financing Transactions
Endovascular Engineering Funding Round
Endovascular Engineering, based in Menlo Park, secured $80 million from Gilde Healthcare Partners, Norwest Venture Partners and 415 CAPITAL.
Transaction Overview
Company Name
Announced On
4/7/2026
Transaction Type
Venture Equity
Amount
$80,000,000
Round
Series C
Investors
Gilde Healthcare Partners (Lead Investor)
Norwest Venture Partners (Lead Investor)
Proceeds Purpose
The company intends to use the funds to supports commercialization of its new Helo Thrombectomy Platform for the treatment of pulmonary embolism, the third leading cause of cardiovascular death.
Company Information
Company Status
Private & Independent
Industry
Engineering
Mailing Address
3925 Bohannon Drive 300
Menlo Park, CA 94025
USA
Menlo Park, CA 94025
USA
Phone
Email Address
Overview
Endovascular Engineering, Inc. ("E2"), is a mission-driven, venture-backed company focused on the development and deployment of next generation clot removal technologies that target venous thromboembolism.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Dan Rose
Browse more venture capital transactions:
Prev: 4/7/2026: True Footage venture capital transaction
Next: 4/7/2026: Cyberhill Partners venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs